Findings include exclusion of people with cognitive, visual, hearing, mobility, and other disabilities, without documented justification
FRIDAY, Oct. 14, 2022 (HealthDay News) — People with disabilities are commonly excluded from clinical trials, according to a report published in the October issue of Health Affairs.
Willyanne DeCormier Plosky, Ph.D., from Brigham and Women’s Hospital in Boston, and colleagues analyzed 97 recent interventional protocols in four therapeutic areas registered on ClinicalTrials.gov to assess disability status of trial participants.
The researchers found that 85 percent of protocols allowed broad investigator discretion to determine eligibility, whereas only 18 percent explicitly permitted people with disabilities to use forms of support (e.g., supported decision making or assistive devices) to facilitate study participation. Eligibility criteria limiting participation of people with disabilities included exclusions for psychiatric (68 percent), substance use (62 percent), HIV or hepatitis (53 percent), cognitive or intellectual (42 percent), visual (34 percent), hearing (10 percent), mobility (9 percent), long-term care (6 percent), and speech and communication (3 percent) disability-related domains. Only 24 percent of these exclusions provided documented justification.
“We recommend greater scrutiny of study eligibility criteria, scientific or ethical justification of exclusions, and accessible study design,” the authors write.
One author disclosed financial ties to the Takeda Pharmaceuticals Ethics Advisory Council.
Most Adults With Moderate-to-Severe Ulcerative Colitis Ineligible for RCTs
Huge Gap Exists Between Regulatory Authorization, Clinical Validation of AI Medical Devices
Randomized Trial of Early Vitrectomy Feasible for Postoperative Endophthalmitis
Once-Weekly Oral Islatravir-Lenacapavir Noninferior to Daily B/F/TAF in HIV
December 2024 to 2025 Saw Significant Increase in Leucovorin Dispensing
Dexrazoxane Offers Lasting Doxorubicin Cardioprotective Effect in Childhood Cancer Survivors
Long-Term Medication Adherence Tied to Lower Cardiovascular Event Rate in Type 2 Diabetes
28 Percent of U.S. Adults With HTN Eligible for Treatment Under New Guidelines